drugset / Trial / NCT06161675

Feasibility of Delivering VergeRx at FQHCs

NCT06161675

Active not recruiting 100 enrolled University of Virginia
RandomizedFactorialSingle-blindTreatment

Summary

Cigarette smoking in the U.S. is highest among low income and Medicaid insured adults, and unfortunately, low-income smokers are even less likely to attempt to quit, less likely to use evidence-based treatments, and thus less likely to be successful. Federally Qualified Health Centers (FQHCs), which generally provide healthcare services to low income and Medicaid insured patients, are more likely to serve individuals who use tobacco and are required to report tobacco use screening rates and their delivery of cessation interventions. Thus, FQHCs are an ideal community-partner to reach low-income smokers, particularly smokers who are not currently seeking treatment. To address this gap, the investigators developed a pharmacist-delivered smoking cessation intervention to help facilitate nicotine replacement therapy medication adherence among smokers. The proposed study aims to examine the feasibility of delivering the pharmacist-delivered smoking cessation intervention to FQHC patients who are ready to quit, and expanding the intervention for smokers not ready to quit by adding 2 pre-quit sessions focused on rate reduction. The investigators will also determine facilitators and barriers to adopting and implementing the program in FQHCs.

Timeline

Start
2024-09-23
Primary completion
2025-01-31
Completion
2026-07-01

Drugs

EvaluationDrugModalityDoseRoute
Background Nicotine Unknown Other
Background Nicotine Unknown Oral

Indications